Gómez-Vázquez HM

Idioma: Español
Referencias bibliográficas: 19
Paginas: 645-649
Archivo PDF: 500.90 Kb.

RESUMEN

Objetivo: medir qué porcentaje de pacientes tiene un QTc›450, es decir, prolongado.
Material y método: estudio observacional prospectivo en el que se efectuó electrocardiograma y cálculo de fórmula de QTcorregido por fórmula de Bazett en 150 pacientes consecutivos de la consulta de Medicina Interna mayores de 40 años, en los que el clínico encontrara cualquier indicación para tomar un trazo de electrocardiograma.
Resultados: en 150 pacientes consecutivos se encontró un promedio de QTc de 425.69, límites: 357-511 y distribución normal; 20 pacientes (13%) tuvieron un QTc igual o superior a 450.
Conclusiones: debido a que se encontró un QTc prolongado en 13% de los pacientes consecutivos, estables de consulta, se concluye que debemos medir el intervalo siempre antes de recetar azitromicina o claritromicina, aunque el riesgo por cada oportunidad de prescripción sea bajo.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Asadi L, Eurich DT, Gamble JM, Minhas-Sandhu JK, et al. Guideline adherence and macrolides reduced mortality in outpatients with pneumonia. Respir Med 2012;106:451-458.

2. Albert R, Connett J, Bailey W, Casaburi R, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011;365:689-698.

3. Mandell LA, Marrie TJ, Grossman RF, Chow AW, Hyland RH, CAP Working Group. Summary of the Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Disease Society and the Canadian Thoracic Society. Can Respir J 2000;7:371-382.

4. Kanoh S, Rubin BK. Mechanisms of action and clinical application of macrolides as immunomodulatory medications. Clin Microbiol Rev 2010;23:590-615.

5. Mortensen EM, Halm EA, Pugh M, et al. Association of azithromycin with mortality and cardiovascular events among older patients hospitalized with pneumonia JAMA 2014;311:2199-2298.

6. Mosholder AD, Mathew J, Alexander JJ, Smith H, Nambiar S. Cardiovascular risks with azithromycin and other antibacterial drugs. N Engl J Med 2014;368:1665-1668.

7. Ray WA, Murray KT, Meredith S, Narasimhulu SS, et al. Azithromycin and the risk of cardiovascular death. N Engl J Med 2012;366:1881-1890.

8. COPD Clinical Research Network. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011;365:689-698.

9. Criner GJ, Bourbeau J, Diekemper RL, Ouellette DR, et al. Prevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline. Chest 2015;147:894-942.

10. Postma DF, Werkhoven CH, van Elden LJ, Thijsen SF, et al. Antibiotic treatment strategies for community-acquired pneumonia in adults. N Engl J Med 2015;372:1312-1323.

11. Svanström HM, Pasternak B, Hviid A. Use of azithromycin and death from cardiovascular causes. N Engl J Med 2013;368:1704-1712.

12. Wenzel RP, Fowler AA 3rd, Edmond MB. Antibiotic prevention of acute exacerbations of COPD. N Engl J Med 2012;367:340-347.

13. Abu-Gharbieh E, Vasina V, Poluzzi E, De Ponti F. Antibacterial macrolides: a drug class with a complex pharmacological profile. Pharmacol Res 2004;50:211-222.

14. Kertland H. Should azithromycin no longer be considered a drug of choice for community-acquired pneumonia because of its potential to cause cardiovascular death? Can J Hosp Pharm 2013;66:328-331.

15. Wenzel RP, Fowler A, Edmond M. Antibiotic prevention of acute exacerbations of COPD. N Engl J Med 2012;367:340-347.

16. Seemungal TA, Wilkinson TM, Hurst JR, Perera WR, et al. Long-term erithromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med 2008;178:1139-1147.

17. Martinez FJ, Curtis JL, Albert R. Role of macrolide therapy in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2008;3:331-350.

18. Milstone A. Use of azithromycin in the treatment of acute exacerbations of COPD. Int J Chron Obstruct Pulmon Dis 2008;3:515-520.

19. Barbara AL, David NJ. Drugs and the QT interval — Caveat Doctor. N Engl J Med 2004;351:1053-1056.